1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. New Jersey >
  6. Duchesnay Acquires Shionogi - Osphena

M&A Deal Summary

Duchesnay Acquires Shionogi - Osphena

On March 10, 2017, Duchesnay acquired life science company Shionogi - Osphena from Shionogi

Acquisition Highlights
  • This is Duchesnay’s 1st transaction in the Life Science sector.
  • This is Duchesnay’s 1st transaction in the United States.
  • This is Duchesnay’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2017-03-10
Target Shionogi - Osphena
Sector Life Science
Buyer(s) Duchesnay
Sellers(s) Shionogi
Deal Type Divestiture

Target

Shionogi - Osphena

Florham Park, New Jersey, United States
Shionogi, Inc. - Osphena is an oral, non-hormonal prescription medication indicated for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Duchesnay

Blainville, Quebec, Canada
Category Company
Sector Life Science
DESCRIPTION

Duchesnay, Inc. is a specialty pharmaceutical company with a long-standing commitment to women's health. In addition to filling the void in terms of scientific research, education and information and developing pharmacological solutions that are safe for use during pregnancy and breastfeeding, Duchesnay is equally committed to ensuring women's health and improving their quality of life at every stage.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: New Jersey M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2017 M&A 1 of 1

Seller(S) 1

SELLER

Shionogi

Florham Park, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

Shionogi Inc. is the U.S.-based group company of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company. Shionogi Inc., develops and commercializes pharmaceutical products that address unmet medical needs. Together with our Japanese corporate parent, Shionogi has been providing innovative medicines essential to people's health for over 130 years. This partnership sets the stage for further expansion of our global business with expectations for Shionogi Inc. to become an even more significant contributor to our world-wide results.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Divestiture M&A Deals 2 of 2
State: New Jersey M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2017 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-06 Shionogi - Keflex

United States

Shionogi - Keflex (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-26 Qpex Biopharma

San Diego, California, United States

Qpex Biopharma is a biopharmaceutical company that develops multiple antibiotic drug that combats antimicrobial resistance. Qpex Biopharma is based in San Diego, California.

Buy -
Mergr

Solution for

Product

Company

Legal